Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg; Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg; Drug: Umeclidinium 62.5 mcg; Device: Placebo ELLIPTA inahler; Drug: Albuterol/Salbutamol
Sponsor: GlaxoSmithKline
Not yet recruiting – verified April 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days